Novavax (NVAX)
(Real Time Quote from BATS)
$12.81 USD
+0.01 (0.08%)
Updated Sep 24, 2024 10:16 AM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Novavax (NVAX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$18.17 | $31.00 | $9.00 | 41.95% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Novavax comes to $18.17. The forecasts range from a low of $9.00 to a high of $31.00. The average price target represents an increase of 41.95% from the last closing price of $12.80.
Analyst Price Targets (6 )
Broker Rating
Novavax currently has an average brokerage recommendation (ABR) of 2.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 2.33 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, three are Strong Buy, representing 50% of all recommendations. A month ago, Strong Buy represented 50%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 0 |
ABR | 2.33 | 2.33 | 2.33 | 2.33 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/23/2024 | B. Riley Securities | Mayank Mamtani | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Brendan Smith | Hold | Hold |
3/1/2024 | H.C. Wainwright & Co. | Vernon Bernardino | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.33 |
ABR (Last week) | 2.33 |
# of Recs in ABR | 6 |
Average Target Price | $18.17 |
LT Growth Rate | 27.10% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 80 of 253 |
Current Quarter EPS Est: | -0.91 |
NVAX FAQs
Novavax, Inc. (NVAX) currently has an average brokerage recommendation (ABR) of 2.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 6 brokerage firms.
The average price target for Novavax, Inc. (NVAX) is $18.17. The current on short-term price targets is based on 6 reports.
The forecasts for Novavax, Inc. (NVAX) range from a low of $9 to a high of $31. The average price target represents a increase of $41.95 from the last closing price of $12.80.
The current UPSIDE for Novavax, Inc. (NVAX) is 41.95%
Based on short-term price targets offered by six analysts, the average price target for Novavax comes to $18.17. The forecasts range from a low of $9.00 to a high of $31.00. The average price target represents an increase of 41.95% from the last closing price of $12.80.